Saracatinib Delays the Progression of Renal Interstitial Fibrosis by Inhibiting the Wnt/β-Catenin Pathway
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Saracatinib inhibits Fyn kinase, a key driver of renal interstitial fibrosis in chronic kidney disease (CKD). This targeted approach shows promise for treating CKD by reducing fibrosis and improving kidney function markers.
Area Of Science
- Nephrology
- Molecular Biology
- Pharmacology
Background
- Renal interstitial fibrosis is a hallmark of chronic kidney disease (CKD) progression.
- The Wnt/β-catenin signaling pathway is implicated in renal fibrosis, but its precise role is not fully understood.
Purpose Of The Study
- To investigate the role of Fyn kinase in renal interstitial fibrosis.
- To evaluate saracatinib's therapeutic potential for CKD by targeting Fyn kinase and the Wnt/β-catenin pathway.
Main Methods
- Analysis of renal tissue from CKD patients and a rat model of unilateral ureteral obstruction (UUO).
- Administration of saracatinib to UUO rats to assess its effects on fibrosis markers and Wnt/β-catenin pathway activation.
Main Results
- Upregulation of Fyn kinase and Wnt/β-catenin pathway activation observed in fibrotic kidney tissues.
- Saracatinib inhibited Fyn kinase, blocking β-catenin phosphorylation and reducing markers of renal fibrosis and improving kidney function in rats.
Conclusions
- Saracatinib effectively inhibits the Fyn/Wnt/β-catenin pathway in renal interstitial fibrosis.
- Saracatinib represents a potential novel therapeutic strategy for treating chronic kidney disease.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
The gene encoding the main signaling molecules of the Wnt signaling pathways (the Wnt proteins) was discovered almost four decades ago by Nüsslein-Volhard and Wieschaus. They identified and originally named the gene "wingless" (wg) after a phenotype discovered during their landmark genetic screen in Drosophila for body pattern defects. At around the same time, another researcher named Harold Varmus found that a murine tumor virus activates the mammalian wg homolog, Int-1, which...
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...